Vanda Pharmaceuticals (NASDAQ:VNDA) Rating Lowered to “Sell” at Wall Street Zen

Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Friday.

VNDA has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, November 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 8th. B. Riley assumed coverage on Vanda Pharmaceuticals in a research report on Wednesday, November 5th. They set a “buy” rating and a $11.00 price objective for the company. Finally, Cantor Fitzgerald decreased their price objective on Vanda Pharmaceuticals from $13.00 to $11.00 and set an “overweight” rating for the company in a report on Thursday, October 30th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Vanda Pharmaceuticals Stock Up 1.0%

VNDA stock opened at $5.36 on Friday. The business’s 50-day simple moving average is $5.00 and its 200 day simple moving average is $4.70. Vanda Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $5.70. The company has a market cap of $316.46 million, a PE ratio of -3.77 and a beta of 0.78.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.07). Vanda Pharmaceuticals had a negative return on equity of 16.44% and a negative net margin of 39.70%.The company had revenue of $56.26 million for the quarter, compared to analyst estimates of $58.73 million. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Vanda Pharmaceuticals will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of VNDA. Russell Investments Group Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 5,328 shares during the period. CWM LLC lifted its stake in Vanda Pharmaceuticals by 424.6% during the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 7,575 shares during the last quarter. PVG Asset Management Corp acquired a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at $48,000. Quarry LP bought a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $53,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $72,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.